1 / 16

Secure Access Framework for BioMedBridges Project

This presentation outlines the objectives, work description, deliverables, and milestones of WP5 in the BioMedBridges project. The aim is to establish a security framework compliant with legal and ethical requirements on national and European levels. It will use existing European e-Infrastructure concepts for authentication and authorization services. The presentation identifies partners, tasks, responsibilities, and interactions within WP5 and with other project components. Next steps include member identification, regular meetings, and focusing on specific tasks. The presentation also raises questions for dialogue on shared data categories, legal considerations, technical requirements, and data access levels.

astra
Download Presentation

Secure Access Framework for BioMedBridges Project

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WP 5: Secure access C. Ohmann (chair), K. Kuhn (co-chair) BioMedBridges Kick-off Meeting 5-6 March 2012, Hinxton, Cambridge

  2. Aim of the presentation • partners • objectives • description of work • deliverables • milestones • interactions • next steps

  3. Objective WP5 will establish a security framework which is compliant with legal and ethical requirements on the national and European level. It will both use security policies compliant with European regulations, and take into account policies and consent and use agreements of the participating infrastructures. For implementation of authentication and authorization services, existing standards, solutions, and concepts of European e-Infrastructures will be used in adequate way.

  4. WP-members (preliminary) • C. Ohmann (Heinrich-Heine-Universitaet Düsseldorf, Germany, partner 5) • K. Kuhn (Klinikum Rechts der Isar der TU München, Germany, partner 7) • J. Ellenberg, D. Arendt, A. Keppler, A. Brazma (European Molecular Biology Laboratory, UK, partner 1) • A. Pollex-Krüger (Technologische und Methodenplattform für die vernetzte Forschung e.V. , Germany, partner 10) • M. Winn (Science and Technology Facilities Council, UK, partner 4) • M. Hrabé, C. Lengger, M. Räß, R. Ludwig, R. Frank (Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Germany, partner 11) • S. Klein, W. Niessen (Erasmus Universitair Medisch Centrum Rotterdam, • Netherlands, partner 9) • NN (Forschungsverbund Berlin e.V., Germany, partner 6) • H. Raoul, C. Carbonelle (Institut National de la Santé et de la Recherche Médicale, France, partner 14)

  5. WP5 tasks WT1-4: Regulations, requirements and design aspects WT5-8: Security implementation

  6. WP5 Tasks / Responsabilities

  7. WP5 Tasks / Responsabilities

  8. WP5 Tasks / Responsabilities

  9. WP5 Tasks / Responsabilities

  10. WP5 Tasks / Responsabilities

  11. Deliverables

  12. Milestones

  13. Resources (PM)

  14. Interaction • Strong interaction with other WPs from the beginning, especially WP3,4 and 5 and the use cases (WP6-WP10) • Close link to the BMS infrastructures via the partners involved (BBMRI, EATRIS, ECRIN, ELIXIR, Infrafrontier, INSTRUCT, EMBRC, ERINHA, EU-Openscreen, Euro-Bioimaging) • Interaction with other EU-projects in order to learn from existing/ongoing activities (e.g. Transform, p-medicine, EHR4CR)

  15. Next steps • identification of WP-members from the participating partners • regular telephone conferences of WP 5 (at least every 4 weeks) • face-to-face meeting of WP 5 (e.g. June 2012) • in the first half year of 2012 concentration on • - WT1 • - WT3.1 • - WT3.2 • - WT3.3

  16. WP5Questions for the dialogue between use cases and infrastructures What can be shared What are the categories of available data Genetic, omics Clinical: diagnoses, med histories, medication What does the legal and/or contractual situation allow? Open / anonymous / derived data? informed consent available? Access restrictions? What is the technical basis offered See WP4: browsing, programmatic access, RDF What is needed, what is the purpose individual data (anonymized?) vs summaries/derived data How will data be aggregated? Are access tiers needed, e.g. for members only?

More Related